Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alimera Sciences Inc ALIM

Healthcare
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye ... see more

Recent & Breaking News (NDAQ:ALIM)

Alimera Sciences Reports Fourth Quarter and FY 2021 Results

GlobeNewswire February 24, 2022

Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology

GlobeNewswire February 23, 2022

Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update

GlobeNewswire February 17, 2022

Alimera Sciences Announces Launch of ILUVIEN® for Uveitis in Spain

GlobeNewswire February 7, 2022

Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference

GlobeNewswire February 4, 2022

36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022

Accesswire January 28, 2022

Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences

GlobeNewswire January 5, 2022

Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors

GlobeNewswire December 1, 2021

Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences

GlobeNewswire November 9, 2021

Alimera Sciences Announces Third Quarter 2021 Financial Results

GlobeNewswire October 28, 2021

Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate Update

GlobeNewswire October 21, 2021

Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema

GlobeNewswire October 13, 2021

Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

GlobeNewswire September 2, 2021

Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium

GlobeNewswire August 24, 2021

Alimera Sciences to Present at the Sidoti & Company Fall 2017 Conference

GlobeNewswire September 19, 2017

Alimera Sciences Announces ILUVIEN® now available in Ireland

GlobeNewswire September 12, 2017

Weather Related Conditions Cancels Alimera Sciences Presentation at Rodman & Renshaw Global Investment Conference

GlobeNewswire September 11, 2017

Alimera Sciences Announces 9 Clinical Presentations and a Sponsored Symposium at 17th Euretina Congress

GlobeNewswire September 5, 2017

Alimera Sciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

GlobeNewswire August 31, 2017

Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in France

GlobeNewswire August 29, 2017